GSK Sees Cervarix Cross-Protection, Age Range As Key Points Of Differentiation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline expects to highlight a broad age range and cross-protection against multiple viral strains to differentiate its human papilloma virus vaccine Cervarix from Merck’s competing vaccine Gardasil.